Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Scalp Angiosarcoma Remission with Bevacizumab and Radiotherapy without Surgery: A Case Report and Review of the Literature</title><author><name sortKey="De Yao, Jocelyn T" sort="De Yao, Jocelyn T" uniqKey="De Yao J" first="Jocelyn T." last="De Yao">Jocelyn T. De Yao</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Sun, Danyu" sort="Sun, Danyu" uniqKey="Sun D" first="Danyu" last="Sun">Danyu Sun</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Powell, Angela T" sort="Powell, Angela T" uniqKey="Powell A" first="Angela T." last="Powell">Angela T. Powell</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Rehmus, Esther H" sort="Rehmus, Esther H" uniqKey="Rehmus E" first="Esther H." last="Rehmus">Esther H. Rehmus</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">21647357</idno><idno type="pmc">3103974</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103974</idno><idno type="RBID">PMC:3103974</idno><idno type="doi">10.1155/2011/160369</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">002402</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002402</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Scalp Angiosarcoma Remission with Bevacizumab and Radiotherapy without Surgery: A Case Report and Review of the Literature</title><author><name sortKey="De Yao, Jocelyn T" sort="De Yao, Jocelyn T" uniqKey="De Yao J" first="Jocelyn T." last="De Yao">Jocelyn T. De Yao</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Sun, Danyu" sort="Sun, Danyu" uniqKey="Sun D" first="Danyu" last="Sun">Danyu Sun</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Powell, Angela T" sort="Powell, Angela T" uniqKey="Powell A" first="Angela T." last="Powell">Angela T. Powell</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author><author><name sortKey="Rehmus, Esther H" sort="Rehmus, Esther H" uniqKey="Rehmus E" first="Esther H." last="Rehmus">Esther H. Rehmus</name><affiliation><nlm:aff>NONE</nlm:aff></affiliation><affiliation><nlm:aff>NONE</nlm:aff></affiliation></author></analytic><series><title level="j">Sarcoma</title><idno type="ISSN">1357-714X</idno><idno type="eISSN">1369-1643</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Angiosarcoma (AS) is a rare and aggressive vascular neoplasm with very poor prognosis. Patients with extensive cutaneous AS who are not surgical candidates have very limited options since there is no standard treatment. Treatment options include radiation, chemotherapy, and angiogenesis inhibitor with varying success rates. Here, we report a case an 88 year old patient with extensive scalp angiosarcoma having biopsy proven remission with bevacizumab and radiotherapy without undergoing surgery.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Lydiatt, Wm" uniqKey="Lydiatt W">WM Lydiatt</name></author><author><name sortKey="Shaha, Ar" uniqKey="Shaha A">AR Shaha</name></author><author><name sortKey="Shah, Jp" uniqKey="Shah J">JP Shah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aust, Mr" uniqKey="Aust M">MR Aust</name></author><author><name sortKey="Olsen, Kd" uniqKey="Olsen K">KD Olsen</name></author><author><name sortKey="Lewis, Je" uniqKey="Lewis J">JE Lewis</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fury, Mg" uniqKey="Fury M">MG Fury</name></author><author><name sortKey="Antonescu, Cr" uniqKey="Antonescu C">CR Antonescu</name></author><author><name sortKey="Van Zee, Kj" uniqKey="Van Zee K">KJ van Zee</name></author><author><name sortKey="Brennan, Mf" uniqKey="Brennan M">MF Brennan</name></author><author><name sortKey="Maki, Rg" uniqKey="Maki R">RG Maki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wanebo, Hj" uniqKey="Wanebo H">HJ Wanebo</name></author><author><name sortKey="Koness, Rj" uniqKey="Koness R">RJ Koness</name></author><author><name sortKey="Macfarlane, Jk" uniqKey="Macfarlane J">JK MacFarlane</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mark, Rj" uniqKey="Mark R">RJ Mark</name></author><author><name sortKey="Poen, Jc" uniqKey="Poen J">JC Poen</name></author><author><name sortKey="Tran, Lm" uniqKey="Tran L">LM Tran</name></author><author><name sortKey="Fu, Ys" uniqKey="Fu Y">YS Fu</name></author><author><name sortKey="Juillard, Gf" uniqKey="Juillard G">GF Juillard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Weber, Rs" uniqKey="Weber R">RS Weber</name></author><author><name sortKey="Benjamin, Rs" uniqKey="Benjamin R">RS Benjamin</name></author><author><name sortKey="Peters, Lj" uniqKey="Peters L">LJ Peters</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pawlik, Tm" uniqKey="Pawlik T">TM Pawlik</name></author><author><name sortKey="Paulino, Af" uniqKey="Paulino A">AF Paulino</name></author><author><name sortKey="Mcginn, Cj" uniqKey="Mcginn C">CJ McGinn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hodgkinson, Dj" uniqKey="Hodgkinson D">DJ Hodgkinson</name></author><author><name sortKey="Soule, Eh" uniqKey="Soule E">EH Soule</name></author><author><name sortKey="Woods, Je" uniqKey="Woods J">JE Woods</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Holden, Ca" uniqKey="Holden C">CA Holden</name></author><author><name sortKey="Spittle, Mf" uniqKey="Spittle M">MF Spittle</name></author><author><name sortKey="Jones, Ew" uniqKey="Jones E">EW Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maddox, Jc" uniqKey="Maddox J">JC Maddox</name></author><author><name sortKey="Evans, Hl" uniqKey="Evans H">HL Evans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Willers, H" uniqKey="Willers H">H Willers</name></author><author><name sortKey="Hug, Eb" uniqKey="Hug E">EB Hug</name></author><author><name sortKey="Spiro, Ij" uniqKey="Spiro I">IJ Spiro</name></author><author><name sortKey="Efird, Jt" uniqKey="Efird J">JT Efird</name></author><author><name sortKey="Rosenberg, Ae" uniqKey="Rosenberg A">AE Rosenberg</name></author><author><name sortKey="Wang, Cc" uniqKey="Wang C">CC Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mark, Rj" uniqKey="Mark R">RJ Mark</name></author><author><name sortKey="Tran, Lm" uniqKey="Tran L">LM Tran</name></author><author><name sortKey="Sercarz, J" uniqKey="Sercarz J">J Sercarz</name></author><author><name sortKey="Fu, Ys" uniqKey="Fu Y">YS Fu</name></author><author><name sortKey="Calcaterra, Tc" uniqKey="Calcaterra T">TC Calcaterra</name></author><author><name sortKey="Juillard, Gf" uniqKey="Juillard G">GF Juillard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Freedman, Am" uniqKey="Freedman A">AM Freedman</name></author><author><name sortKey="Reiman, Hm" uniqKey="Reiman H">HM Reiman</name></author><author><name sortKey="Woods, Je" uniqKey="Woods J">JE Woods</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Farhood, Ai" uniqKey="Farhood A">AI Farhood</name></author><author><name sortKey="Hajdu, Si" uniqKey="Hajdu S">SI Hajdu</name></author><author><name sortKey="Shiu, Mh" uniqKey="Shiu M">MH Shiu</name></author><author><name sortKey="Strong, Ew" uniqKey="Strong E">EW Strong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Panje, Wr" uniqKey="Panje W">WR Panje</name></author><author><name sortKey="Moran, Wj" uniqKey="Moran W">WJ Moran</name></author><author><name sortKey="Bostwick, Dg" uniqKey="Bostwick D">DG Bostwick</name></author><author><name sortKey="Kitt, Vv" uniqKey="Kitt V">VV Kitt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Koontz, Bf" uniqKey="Koontz B">BF Koontz</name></author><author><name sortKey="Miles, Ef" uniqKey="Miles E">EF Miles</name></author><author><name sortKey="Rubio, Mad" uniqKey="Rubio M">MAD Rubio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gkalpakiotis, S" uniqKey="Gkalpakiotis S">S Gkalpakiotis</name></author><author><name sortKey="Arenberger, P" uniqKey="Arenberger P">P Arenberger</name></author><author><name sortKey="Vohradnikova, O" uniqKey="Vohradnikova O">O Vohradnikova</name></author><author><name sortKey="Arenbergerova, M" uniqKey="Arenbergerova M">M Arenbergerova</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schlemmer, M" uniqKey="Schlemmer M">M Schlemmer</name></author><author><name sortKey="Reichardt, P" uniqKey="Reichardt P">P Reichardt</name></author><author><name sortKey="Verweij, J" uniqKey="Verweij J">J Verweij</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nagano, T" uniqKey="Nagano T">T Nagano</name></author><author><name sortKey="Yamada, Y" uniqKey="Yamada Y">Y Yamada</name></author><author><name sortKey="Ikeda, T" uniqKey="Ikeda T">T Ikeda</name></author><author><name sortKey="Kanki, H" uniqKey="Kanki H">H Kanki</name></author><author><name sortKey="Kamo, T" uniqKey="Kamo T">T Kamo</name></author><author><name sortKey="Nishigori, C" uniqKey="Nishigori C">C Nishigori</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Holloway, Cl" uniqKey="Holloway C">CL Holloway</name></author><author><name sortKey="Turner, Ar" uniqKey="Turner A">AR Turner</name></author><author><name sortKey="Dundas, Gs" uniqKey="Dundas G">GS Dundas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Eiling, S" uniqKey="Eiling S">S Eiling</name></author><author><name sortKey="Lischner, S" uniqKey="Lischner S">S Lischner</name></author><author><name sortKey="Busch, Jo" uniqKey="Busch J">JO Busch</name></author><author><name sortKey="Rothaupt, D" uniqKey="Rothaupt D">D Rothaupt</name></author><author><name sortKey="Christophers, E" uniqKey="Christophers E">E Christophers</name></author><author><name sortKey="Hauschild, A" uniqKey="Hauschild A">A Hauschild</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lankester, Kj" uniqKey="Lankester K">KJ Lankester</name></author><author><name sortKey="Brown, Rsd" uniqKey="Brown R">RSD Brown</name></author><author><name sortKey="Spittle, Mf" uniqKey="Spittle M">MF Spittle</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Benbenisty, Km" uniqKey="Benbenisty K">KM Benbenisty</name></author><author><name sortKey="Lang, Pg" uniqKey="Lang P">PG Lang</name></author><author><name sortKey="Maize, Jc" uniqKey="Maize J">JC Maize</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pestoni, C" uniqKey="Pestoni C">C Pestoni</name></author><author><name sortKey="Paredes Suarez, C" uniqKey="Paredes Suarez C">C Paredes-Suarez</name></author><author><name sortKey="Peteiro, C" uniqKey="Peteiro C">C Peteiro</name></author><author><name sortKey="Toribio, J" uniqKey="Toribio J">J Toribio</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fata, F" uniqKey="Fata F">F Fata</name></author><author><name sortKey="O Eilly, E" uniqKey="O Eilly E">E O’Reilly</name></author><author><name sortKey="Ilson, D" uniqKey="Ilson D">D Ilson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wollina, U" uniqKey="Wollina U">U Wollina</name></author><author><name sortKey="Fuller, J" uniqKey="Fuller J">J Füller</name></author><author><name sortKey="Graefe, T" uniqKey="Graefe T">T Graefe</name></author><author><name sortKey="Kaatz, M" uniqKey="Kaatz M">M Kaatz</name></author><author><name sortKey="Lopatta, E" uniqKey="Lopatta E">E Lopatta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zietz, C" uniqKey="Zietz C">C Zietz</name></author><author><name sortKey="Rossle, M" uniqKey="Rossle M">M Rössle</name></author><author><name sortKey="Haas, C" uniqKey="Haas C">C Haas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ranpura, V" uniqKey="Ranpura V">V Ranpura</name></author><author><name sortKey="Hapani, S" uniqKey="Hapani S">S Hapani</name></author><author><name sortKey="Chuang, J" uniqKey="Chuang J">J Chuang</name></author><author><name sortKey="Wu, S" uniqKey="Wu S">S Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Agulnik, M" uniqKey="Agulnik M">M Agulnik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="D Damo, D" uniqKey="D Damo D">D D’Adamo</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="case-report"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Sarcoma</journal-id><journal-id journal-id-type="iso-abbrev">Sarcoma</journal-id><journal-id journal-id-type="publisher-id">SRCM</journal-id><journal-title-group><journal-title>Sarcoma</journal-title></journal-title-group><issn pub-type="ppub">1357-714X</issn><issn pub-type="epub">1369-1643</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21647357</article-id><article-id pub-id-type="pmc">3103974</article-id><article-id pub-id-type="doi">10.1155/2011/160369</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Scalp Angiosarcoma Remission with Bevacizumab and Radiotherapy without Surgery: A Case Report and Review of the Literature</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Yao</surname><given-names>Jocelyn T.</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 2</sup></xref><xref ref-type="aff" rid="I2"></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Danyu</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 2</sup></xref><xref ref-type="aff" rid="I2"></xref></contrib><contrib contrib-type="author"><name><surname>Powell</surname><given-names>Angela T.</given-names></name><xref ref-type="aff" rid="I2"><sup>2, 3</sup></xref><xref ref-type="aff" rid="I3"></xref></contrib><contrib contrib-type="author"><name><surname>Rehmus</surname><given-names>Esther H.</given-names></name><xref ref-type="aff" rid="I1"><sup>1, 2</sup></xref><xref ref-type="aff" rid="I2"></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Medicine, Akron General Medical Center, 400 Wabash Avenue, Akron, OH 44307, USA</aff><aff id="I2"><sup>2</sup>Department of Medicine, Northeastern Ohio Universities, College of Medicine and Pharmacy, Rootstown, OH 44272, USA</aff><aff id="I3"><sup>3</sup>Department of Pathology, Akron General Medical Center, 400 Wabash Avenue, Akron, OH 44307, USA</aff><author-notes><corresp id="cor1">*Jocelyn T. De Yao: <email>jdeyao@agmc.org</email></corresp><fn fn-type="other"><p>Academic Editor: Marcus Schlemmer</p></fn></author-notes><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>2</day><month>5</month><year>2011</year></pub-date><volume>2011</volume><elocation-id>160369</elocation-id><history><date date-type="received"><day>18</day><month>10</month><year>2010</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2011</year></date></history><permissions><copyright-statement>Copyright © 2011 Jocelyn T. De Yao et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Angiosarcoma (AS) is a rare and aggressive vascular neoplasm with very poor prognosis. Patients with extensive cutaneous AS who are not surgical candidates have very limited options since there is no standard treatment. Treatment options include radiation, chemotherapy, and angiogenesis inhibitor with varying success rates. Here, we report a case an 88 year old patient with extensive scalp angiosarcoma having biopsy proven remission with bevacizumab and radiotherapy without undergoing surgery.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Angiosarcoma (AS) is a rare and aggressive vascular neoplasm comprising less than 2% of all soft tissue sarcomas [<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B3" ref-type="bibr">3</xref>]. Angiosarcomas comprise approximately 15% of all head and neck sarcomas [<xref rid="B4" ref-type="bibr">4</xref>–<xref rid="B6" ref-type="bibr">6</xref>] and less than 1% of all malignancies in the region [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Head and neck ASs are frequently seen in the scalp [<xref rid="B1" ref-type="bibr">1</xref>–<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B6" ref-type="bibr">6</xref>–<xref rid="B15" ref-type="bibr">15</xref>] and are common in the elderly population with the mean age greater than 60 years. AS also has a slight predilection for Caucasian patients and the male gender [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B7" ref-type="bibr">7</xref>–<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>–<xref rid="B14" ref-type="bibr">14</xref>]. Prognosis is poor since AS is very aggressive with disease-free survival of less than 50% at five years [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B8" ref-type="bibr">8</xref>–<xref rid="B14" ref-type="bibr">14</xref>] due to its high propensity for local recurrence [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B11" ref-type="bibr">11</xref>]. However, some studies report survival of 10–20% after five years [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B8" ref-type="bibr">8</xref>–<xref rid="B11" ref-type="bibr">11</xref>], which may indicate lesions that are located in the scalp and face have a lower survival rate and higher rate of recurrence [<xref rid="B10" ref-type="bibr">10</xref>]. The most important prognostic factors include tumor size and ability to achieve negative margins with tumor grade also being considered to be a prognostic factor for recurrence [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B12" ref-type="bibr">12</xref>] and overall survival [<xref rid="B11" ref-type="bibr">11</xref>]. Patients with facial or scalp AS of less than 5 cm in size tend to do better than those with tumor size greater than 5 cm [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. Patients with cutaneous AS who are not surgical candidates due to multiple comorbid conditions have limited treatment options. Due to its rapid progression, achieving local control and prevention of metastasis in AS has been a challenge. Few reports have described successful treatment of AS using adjuvant chemotherapy with radiotherapy [<xref rid="B16" ref-type="bibr">16</xref>]. Different treatment modalities used in cutaneous angiosarcoma are depicted in <xref ref-type="table" rid="tab1">Table 1</xref>. Here, we report a successful response of AS to bevacizumab with concurrent radiation therapy in a patient not eligible for surgical intervention.</p></sec><sec id="sec2"><title>2. Case Report</title><p>An 88-year-old Caucasian male with a 37-pack-year history of smoking noticed purplish lumps on his scalp with scaling and erythema for two months prior to presentation. He had a complicated past medical history of Stage II prostate cancer treated with radiation treatments, abdominal aortic aneurysm repair, macular degeneration treated with photodynamic therapy, torn retina, inguinal hernia repair, and four-vessel coronary artery bypass graft. The patient noted the violaceous papules increasing in size and nodularity and extending down to the level of the eyebrows bilaterally. He initially thought the mass was a bruise, but the increase in size prompted him to consult a physician. On examination, the patient had multiple irregularly shaped lesions, largest of which was a 4 cm × 7 cm on the frontal scalp; these lesions were violaceous papules with scaling and erythema as shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. A PET scan showed uptake only on the scalp adjacent to the frontal bone near midline (Stage IIA—T2a N0 M0).</p></sec><sec id="sec3"><title>3. Histology</title><p>Biopsy of the lesion showed irregular channels and ectatic vascular spaces lined by plump hyperchromatic endothelial cells. The histology results were most compatible with moderately differentiated angiosarcoma, as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>, in low magnification (L) and high magnification (R).</p></sec><sec id="sec4"><title>4. Treatment and Followup</title><p>Due to the extent of the disease and his frail state, the patient was a poor surgical candidate; resection, if performed, would have necessitated the removal of his entire scalp, from ear to ear. The patient was started on one pre-irradiation cycle of bevacizumab, which was continued through his course of radiation therapy. Bevacizumab was given 5 mg/kg IV (with calculated dose of 350 mg) every two weeks while on radiation therapy, total of four treatments. His tumor total radiation treatment dose was 6000 rad, in 30 fractions, over 46 days. The patient tolerated the treatment well with skin changes characterized only by erythema and desquamation with residual crusting of the skin. Marked clinical improvement was noted. Side effects also included slight swelling of the eyes with yellowish discharge and pruritus from the radiation treatment. No hypertension or proteinuria was noted. A repeat biopsy performed six months after treatment showed fibrosing granulation tissue, fibrosis, hemosiderin deposition, and dilated vessels not reminiscent of the pattern seen in the original angiosarcoma as shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p><p>Seven months after the completion of bevacizumab and radiation therapy, the patient had a biopsy-proven local recurrence. He was started immediately on an increased dose of bevacizumab 10 mg/kg IV every two weeks, which he tolerated well for three months for a total of 6 doses. He then had a minor stroke, and bevacizumab was discontinued. Weekly paclitaxel was initiated at 80 mg/m<sup>2</sup> and continued for 15 treatments with stable disease. Progression occurred and treatment was changed to pegylated doxorubicin 40 mg/m<sup>2</sup> monthly × 2 treatments without benefit. He expired 23 months after initial presentation due to disease.</p></sec><sec id="sec5"><title>5. Discussion</title><p>Angiosarcoma usually presents as a purple macular ulcerated lesion that is often mistaken for a bruise. Cutaneous angiosarcoma may be categorized as being idiopathic AS of the face and scalp, primary AS of the breast, postradiation AS, or AS arising from chronic lymphedema of the extremity [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B17" ref-type="bibr">23</xref>]. Proposed risk factors for developing cutaneous AS include exposure to vinyl chloride, insecticides, thorium dioxide, and hormones such as anabolic steroids and synthetic estrogen [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. It is also postulated that sun-damaged skin may be a risk factor due to its predilection for Caucasians; however, there is no direct evidence to support this theory [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B17" ref-type="bibr">23</xref>]. A combination of surgery and radiotherapy offers the best survival and is the most common treatment modality used for this very aggressive tumor [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. Surgery remains the first option for treating patients with angiosarcoma of the scalp, but due to its rapid progression, patients may present with disseminated or extensive local disease which make surgery inappropriate [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B8" ref-type="bibr">8</xref>–<xref rid="B15" ref-type="bibr">15</xref>]. Postoperative radiotherapy is employed routinely as it improves survival [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>], although there is still an extremely high rate of recurrence and local failure [<xref rid="B12" ref-type="bibr">12</xref>]. The role of chemotherapy, however, is not well established and has not been proven to increase survival [<xref rid="B12" ref-type="bibr">12</xref>]. </p><p>As a result of the above-mentioned challenges, treatment options are limited, especially since AS is often found in elderly patients who may have many comorbidities and are more prone to adverse treatment reactions. Prospective studies with regard to adjuvant chemotherapy and other treatment combinations are also limited due to the rarity of the disease so there are no specific guidelines with regards to treatment. Radiation therapy dose response has been suggested wherein those receiving greater than 5000 rad have better local control, though larger case numbers are required to validate initially reported successes [<xref rid="B5" ref-type="bibr">5</xref>]. There are case reports of remission with radiotherapy alone; these cases tend to be well-differentiated and exophytic forms of AS [<xref rid="B18" ref-type="bibr">17</xref>]. </p><p>The addition of another therapy to radiation therapy has seen some support over the years; different cases showed AS responding to radiation when biological, angiomodulation, and/or tubulin-affinic substances are given in conjunction with radiation therapy [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B21" ref-type="bibr">18</xref>–<xref rid="B24" ref-type="bibr">20</xref>, <xref rid="B17" ref-type="bibr">23</xref>–<xref rid="B23" ref-type="bibr">26</xref>]. Nevertheless, the overwhelming opinion about chemotherapy is that its utility remains largely undefined [<xref rid="B5" ref-type="bibr">5</xref>]. Major responses have also been reported with paclitaxel, but side effects are dose limiting [<xref rid="B19" ref-type="bibr">24</xref>, <xref rid="B20" ref-type="bibr">25</xref>]. A retrospective study done on 32 advanced angiosarcoma patients by the soft tissue and bone sarcoma EORTC group has 62% response rate in advanced angiosarcomas with paclitaxel, with 6 out of 8 scalp and face angiosarcomas responding [<xref rid="B21" ref-type="bibr">18</xref>]. There are 6 scalp angiosarcoma patients in the EORTC study, with 3 previously treated with radiation therapy (2 with partial response and 1 with progression of disease) and 1 previously treated with doxorubicin (no change with paclitaxel). However, there has been a complete response for 42 months on one patient with scalp angiosarcoma without previous therapy and no previous surgery. Another taxane drug, docetaxel, has been used for cutaneous AS; a retrospective study of nine patients in Japan reported a major response in six patients with reduced neutropenia and peripheral neuropathy compared to paclitaxel [<xref rid="B22" ref-type="bibr">19</xref>]. Published case reports have cited a partial response without surgery [<xref rid="B23" ref-type="bibr">26</xref>] and a sustained complete response after surgery in a patient four years later [<xref rid="B24" ref-type="bibr">20</xref>] following the addition of liposomal doxorubicin [<xref rid="B24" ref-type="bibr">20</xref>, <xref rid="B25" ref-type="bibr">21</xref>, <xref rid="B23" ref-type="bibr">26</xref>]. Eiling et al. reported a case of confirmed histological tumor regression of a nonresectable radioresistant scalp angiosarcoma and cervical lymph node metastasis treated with pegylated liposomal doxorubicin [<xref rid="B25" ref-type="bibr">21</xref>]. Complete remission with liposomal daunorubicin with radiotherapy in unresectable AS has also been published [<xref rid="B26" ref-type="bibr">22</xref>].</p><p>Although our patient had a moderately differentiated AS, the tumor location, the extent of disease, the patient's age, and his comorbidities all pointed to a very poor prognosis. Due to the extent of our patient's disease, it would have been difficult to achieve a tumor-free margin surgically without any disfiguring effects, and radiotherapy alone was initially thought to be insufficient. It is difficult to assess whether our patient's response is due to radiotherapy alone similar to the case reported by Gkalpakiotis et al. [<xref rid="B18" ref-type="bibr">17</xref>] or if bevacizumab improved our patient's response since vascular endothelial growth factor was overexpressed in 80% of angiosarcoma cases [<xref rid="B27" ref-type="bibr">27</xref>]. To our knowledge, this case is the only one to report remission of AS after treatment with bevacizumab and radiotherapy without surgical intervention. In two case reports from the Duke University, 5 mg/kg of bevacizumab was used in one patient and 10 mg/kg for the other in conjunction with radiotherapy as postsurgical treatment [<xref rid="B16" ref-type="bibr">16</xref>]. Our patient was given four treatments of 5 mg/kg of bevacizumab with radiation therapy as a primary treatment without surgical resection and achieved complete clinical response with a negative pathology on biopsy remission. Due to the lack of resection, we cannot report a complete pathologic response. A second course involving a higher dose of bevacizumab for his recurrence led to clinical response after three months but had to be discontinued when patient had a stroke, a known risk of bevacizumab though a meta-analysis done based on 5 randomized controlled trials among 2,288 patients receiving bevacizumab showed no statistical difference of stroke incidence compared to control [<xref rid="B28" ref-type="bibr">28</xref>]. </p><p>With AS being very aggressive and having a very low five-year survival rate, therapy with bevacizumab in conjunction with radiation therapy or as a primary therapy may be one option to improve survival outcomes especially in patients who are not surgical candidates. Currently, there are two phase II clinical trials studying the use of bevacizumab for AS which were not available during our patient's initial diagnosis. One is an open-label multicenter phase II trial assessing the median disease-free progression of AS with the treatment of bevacizumab alone [<xref rid="B29" ref-type="bibr">29</xref>]. The other is the study of adding bevacizumab to the combined chemotherapy of gemcitabine and docetaxel in the treatment of different types of sarcoma including AS [<xref rid="B30" ref-type="bibr">30</xref>]. Both trials are currently recruiting patients. A prospective clinical trial regarding neoadjuvant therapy with bevacizumab possibly also including chemotherapy would be an interesting approach. In the absence of specific treatment guidelines for AS, the addition of bevacizumab to radiation may be one option to offer hope to patients who are deemed nonsurgical candidates.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lydiatt</surname><given-names>WM</given-names></name><name><surname>Shaha</surname><given-names>AR</given-names></name><name><surname>Shah</surname><given-names>JP</given-names></name></person-group><article-title>Angiosarcoma of the head and neck</article-title><source><italic>American Journal of Surgery</italic></source><year>1994</year><volume>168</volume><issue>5</issue><fpage>451</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">7977971</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aust</surname><given-names>MR</given-names></name><name><surname>Olsen</surname><given-names>KD</given-names></name><name><surname>Lewis</surname><given-names>JE</given-names></name><etal></etal></person-group><article-title>Angiosarcomas of the head and neck: clinical and pathologic characteristics</article-title><source><italic>Annals of Otology, Rhinology and Laryngology</italic></source><year>1997</year><volume>106</volume><issue>11</issue><fpage>943</fpage><lpage>951</lpage></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fury</surname><given-names>MG</given-names></name><name><surname>Antonescu</surname><given-names>CR</given-names></name><name><surname>van Zee</surname><given-names>KJ</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name><name><surname>Maki</surname><given-names>RG</given-names></name></person-group><article-title>A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy</article-title><source><italic>Cancer Journal</italic></source><year>2005</year><volume>11</volume><issue>3</issue><fpage>241</fpage><lpage>247</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wanebo</surname><given-names>HJ</given-names></name><name><surname>Koness</surname><given-names>RJ</given-names></name><name><surname>MacFarlane</surname><given-names>JK</given-names></name><etal></etal></person-group><article-title>Head and neck sarcoma: report of the head and neck sarcoma registry</article-title><source><italic>Head and Neck</italic></source><year>1992</year><volume>14</volume><issue>1</issue><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">1624288</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mark</surname><given-names>RJ</given-names></name><name><surname>Poen</surname><given-names>JC</given-names></name><name><surname>Tran</surname><given-names>LM</given-names></name><name><surname>Fu</surname><given-names>YS</given-names></name><name><surname>Juillard</surname><given-names>GF</given-names></name></person-group><article-title>Angiosarcoma: a report of 67 patients and a review of the literature</article-title><source><italic>Cancer</italic></source><year>1996</year><volume>77</volume><issue>11</issue><fpage>2400</fpage><lpage>2406</lpage><pub-id pub-id-type="pmid">8635113</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>RS</given-names></name><name><surname>Benjamin</surname><given-names>RS</given-names></name><name><surname>Peters</surname><given-names>LJ</given-names></name><etal></etal></person-group><article-title>Soft tissue sarcomas of the head and neck in adolescents and adults</article-title><source><italic>American Journal of Surgery</italic></source><year>1986</year><volume>152</volume><issue>4</issue><fpage>386</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">3766868</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlik</surname><given-names>TM</given-names></name><name><surname>Paulino</surname><given-names>AF</given-names></name><name><surname>McGinn</surname><given-names>CJ</given-names></name><etal></etal></person-group><article-title>Cutaneous angiosarcoma of the scalp: a multidisciplinary approach</article-title><source><italic>Cancer</italic></source><year>2003</year><volume>98</volume><issue>8</issue><fpage>1716</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">14534889</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgkinson</surname><given-names>DJ</given-names></name><name><surname>Soule</surname><given-names>EH</given-names></name><name><surname>Woods</surname><given-names>JE</given-names></name></person-group><article-title>Cutaneous angiosarcoma of the head and neck</article-title><source><italic>Cancer</italic></source><year>1979</year><volume>44</volume><issue>3</issue><fpage>1106</fpage><lpage>1113</lpage><pub-id pub-id-type="pmid">573173</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holden</surname><given-names>CA</given-names></name><name><surname>Spittle</surname><given-names>MF</given-names></name><name><surname>Jones</surname><given-names>EW</given-names></name></person-group><article-title>Angiosarcoma of the face and scalp, prognosis and treatment</article-title><source><italic>Cancer</italic></source><year>1987</year><volume>59</volume><issue>5</issue><fpage>1046</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">3815265</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maddox</surname><given-names>JC</given-names></name><name><surname>Evans</surname><given-names>HL</given-names></name></person-group><article-title>Angiosarcoma of skin and soft tissue: a study of forty-four cases</article-title><source><italic>Cancer</italic></source><year>1981</year><volume>48</volume><issue>8</issue><fpage>1907</fpage><lpage>1921</lpage><pub-id pub-id-type="pmid">7197190</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willers</surname><given-names>H</given-names></name><name><surname>Hug</surname><given-names>EB</given-names></name><name><surname>Spiro</surname><given-names>IJ</given-names></name><name><surname>Efird</surname><given-names>JT</given-names></name><name><surname>Rosenberg</surname><given-names>AE</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name></person-group><article-title>Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: patterns of failure and prognostic factors</article-title><source><italic>International Journal of Radiation Oncology Biology Physics</italic></source><year>1995</year><volume>33</volume><issue>3</issue><fpage>585</fpage><lpage>593</lpage></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mark</surname><given-names>RJ</given-names></name><name><surname>Tran</surname><given-names>LM</given-names></name><name><surname>Sercarz</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>YS</given-names></name><name><surname>Calcaterra</surname><given-names>TC</given-names></name><name><surname>Juillard</surname><given-names>GF</given-names></name></person-group><article-title>Angiosarcoma of the head and neck: the UCLA experience 1955 through 1990</article-title><source><italic>Archives of Otolaryngology—Head and Neck Surgery</italic></source><year>1993</year><volume>119</volume><issue>9</issue><fpage>973</fpage><lpage>978</lpage><pub-id pub-id-type="pmid">8357598</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>AM</given-names></name><name><surname>Reiman</surname><given-names>HM</given-names></name><name><surname>Woods</surname><given-names>JE</given-names></name></person-group><article-title>Soft-tissue sarcomas of the head and neck</article-title><source><italic>American Journal of Surgery</italic></source><year>1989</year><volume>158</volume><issue>4</issue><fpage>367</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">2802043</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhood</surname><given-names>AI</given-names></name><name><surname>Hajdu</surname><given-names>SI</given-names></name><name><surname>Shiu</surname><given-names>MH</given-names></name><name><surname>Strong</surname><given-names>EW</given-names></name></person-group><article-title>Soft tissue sarcomas of the head and neck in adults</article-title><source><italic>American Journal of Surgery</italic></source><year>1990</year><volume>160</volume><issue>4</issue><fpage>365</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">2221235</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panje</surname><given-names>WR</given-names></name><name><surname>Moran</surname><given-names>WJ</given-names></name><name><surname>Bostwick</surname><given-names>DG</given-names></name><name><surname>Kitt</surname><given-names>VV</given-names></name></person-group><article-title>Angiosarcoma of the head and neck: review of 11 cases</article-title><source><italic>Laryngoscope</italic></source><year>1986</year><volume>96</volume><issue>12</issue><fpage>1381</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">3784742</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koontz</surname><given-names>BF</given-names></name><name><surname>Miles</surname><given-names>EF</given-names></name><name><surname>Rubio</surname><given-names>MAD</given-names></name><etal></etal></person-group><article-title>Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies</article-title><source><italic>Head and Neck</italic></source><year>2008</year><volume>30</volume><issue>2</issue><fpage>262</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">17685450</pub-id></element-citation></ref><ref id="B18"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gkalpakiotis</surname><given-names>S</given-names></name><name><surname>Arenberger</surname><given-names>P</given-names></name><name><surname>Vohradnikova</surname><given-names>O</given-names></name><name><surname>Arenbergerova</surname><given-names>M</given-names></name></person-group><article-title>Successful radiotherapy of facial angiosarcoma</article-title><source><italic>International Journal of Dermatology</italic></source><year>2008</year><volume>47</volume><issue>11</issue><fpage>1190</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">18986458</pub-id></element-citation></ref><ref id="B21"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlemmer</surname><given-names>M</given-names></name><name><surname>Reichardt</surname><given-names>P</given-names></name><name><surname>Verweij</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group</article-title><source><italic>European Journal of Cancer</italic></source><year>2008</year><volume>44</volume><issue>16</issue><fpage>2433</fpage><lpage>2436</lpage><pub-id pub-id-type="pmid">18771914</pub-id></element-citation></ref><ref id="B22"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagano</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Kanki</surname><given-names>H</given-names></name><name><surname>Kamo</surname><given-names>T</given-names></name><name><surname>Nishigori</surname><given-names>C</given-names></name></person-group><article-title>Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients</article-title><source><italic>Cancer</italic></source><year>2007</year><volume>110</volume><issue>3</issue><fpage>648</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">17582627</pub-id></element-citation></ref><ref id="B24"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holloway</surname><given-names>CL</given-names></name><name><surname>Turner</surname><given-names>AR</given-names></name><name><surname>Dundas</surname><given-names>GS</given-names></name></person-group><article-title>Cutaneous angiosarcoma of the scalp: a case report of sustained complete response following liposomal doxorubicin and radiation therapy</article-title><source><italic>Sarcoma</italic></source><year>2005</year><volume>9</volume><issue>1-2</issue><fpage>29</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">18521414</pub-id></element-citation></ref><ref id="B25"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eiling</surname><given-names>S</given-names></name><name><surname>Lischner</surname><given-names>S</given-names></name><name><surname>Busch</surname><given-names>JO</given-names></name><name><surname>Rothaupt</surname><given-names>D</given-names></name><name><surname>Christophers</surname><given-names>E</given-names></name><name><surname>Hauschild</surname><given-names>A</given-names></name></person-group><article-title>Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin</article-title><source><italic>British Journal of Dermatology</italic></source><year>2002</year><volume>147</volume><issue>1</issue><fpage>150</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">12100199</pub-id></element-citation></ref><ref id="B26"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lankester</surname><given-names>KJ</given-names></name><name><surname>Brown</surname><given-names>RSD</given-names></name><name><surname>Spittle</surname><given-names>MF</given-names></name></person-group><article-title>Complete resolution of angiosarcoma of the scalp with liposomal daunorubicin and radiotherapy</article-title><source><italic>Clinical Oncology</italic></source><year>1999</year><volume>11</volume><issue>3</issue><fpage>208</fpage><lpage>210</lpage><pub-id pub-id-type="pmid">10465481</pub-id></element-citation></ref><ref id="B17"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benbenisty</surname><given-names>KM</given-names></name><name><surname>Lang</surname><given-names>PG</given-names></name><name><surname>Maize</surname><given-names>JC</given-names></name></person-group><article-title>Extensive angiosarcoma on chronically sun-damaged skin</article-title><source><italic>American Journal of Clinical Dermatology</italic></source><year>2004</year><volume>5</volume><issue>1</issue><fpage>53</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">14979744</pub-id></element-citation></ref><ref id="B19"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pestoni</surname><given-names>C</given-names></name><name><surname>Paredes-Suarez</surname><given-names>C</given-names></name><name><surname>Peteiro</surname><given-names>C</given-names></name><name><surname>Toribio</surname><given-names>J</given-names></name></person-group><article-title>Early detection of cutaneous angiosarcoma of the face and scalp and treatment with placitaxel</article-title><source><italic>Journal of the European Academy of Dermatology and Venereology</italic></source><year>2005</year><volume>19</volume><issue>3</issue><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">15857466</pub-id></element-citation></ref><ref id="B20"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fata</surname><given-names>F</given-names></name><name><surname>O’Reilly</surname><given-names>E</given-names></name><name><surname>Ilson</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Paclitaxel in the treatment of patients with anglosarcoma of the scalp or face</article-title><source><italic>Cancer</italic></source><year>1999</year><volume>86</volume><issue>10</issue><fpage>2034</fpage><lpage>2037</lpage><pub-id pub-id-type="pmid">10570428</pub-id></element-citation></ref><ref id="B23"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollina</surname><given-names>U</given-names></name><name><surname>Füller</surname><given-names>J</given-names></name><name><surname>Graefe</surname><given-names>T</given-names></name><name><surname>Kaatz</surname><given-names>M</given-names></name><name><surname>Lopatta</surname><given-names>E</given-names></name></person-group><article-title>Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy</article-title><source><italic>Journal of Cancer Research and Clinical Oncology</italic></source><year>2001</year><volume>127</volume><issue>6</issue><fpage>396</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">11414200</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zietz</surname><given-names>C</given-names></name><name><surname>Rössle</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up- regulation in angiosarcomas</article-title><source><italic>American Journal of Pathology</italic></source><year>1998</year><volume>153</volume><issue>5</issue><fpage>1425</fpage><lpage>1433</lpage><pub-id pub-id-type="pmid">9811333</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranpura</surname><given-names>V</given-names></name><name><surname>Hapani</surname><given-names>S</given-names></name><name><surname>Chuang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name></person-group><article-title>Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials</article-title><source><italic>Acta Oncologica</italic></source><year>2010</year><volume>49</volume><issue>3</issue><fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="pmid">20156114</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Agulnik</surname><given-names>M</given-names></name></person-group><article-title>Bevacizumab in treating patients with angiosarcoma</article-title><comment>2010, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00288015?term=NCT00288015&rank=1">http://clinicaltrials.gov/ct2/show/NCT00288015?term=NCT00288015&rank=1</ext-link></comment></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>D’Adamo</surname><given-names>D</given-names></name></person-group><article-title>Gemcitabine and docetaxel with bevacizumab in selected sarcoma subtypes</article-title><comment>2011, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/NCT00887809?term=NCT00887809&rank=1">http://clinicaltrials.gov/ct2/show/NCT00887809?term=NCT00887809&rank=1</ext-link></comment></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><graphic xlink:href="SRCM2011-160369.001"></graphic></fig><fig id="fig2" position="float"><label>Figure 2</label><graphic xlink:href="SRCM2011-160369.002"></graphic></fig><fig id="fig3" position="float"><label>Figure 3</label><graphic xlink:href="SRCM2011-160369.003"></graphic></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Different treatments used in cutaneous angiosarcoma.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="left" rowspan="1" colspan="1">Type of literature</th><th align="left" rowspan="1" colspan="1">Angiosarcoma type</th><th align="left" rowspan="1" colspan="1">Treatment</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Koontz et al. 2008 [<xref rid="B16" ref-type="bibr">16</xref>] </td><td align="left" rowspan="2" colspan="1">Case reports</td><td align="left" rowspan="1" colspan="1">(1) Nasal area</td><td align="left" rowspan="1" colspan="1">(1) Bevacizumab + XRT + SX</td><td align="left" rowspan="1" colspan="1">(1) CR, 26 mos response duration</td></tr><tr><td align="left" rowspan="1" colspan="1">(2) Nasal area</td><td align="left" rowspan="1" colspan="1">(2) Bevacizumab + XRT + SX</td><td align="left" rowspan="1" colspan="1">(2) CR, 8.5 mos response duration </td></tr><tr><td align="center" colspan="5" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="1" colspan="1">Gkalpakiotis et al. 2008 [<xref rid="B18" ref-type="bibr">17</xref>]</td><td align="left" rowspan="1" colspan="1">Case report</td><td align="left" rowspan="1" colspan="1">Well-differentiated exophytic-face</td><td align="left" rowspan="1" colspan="1">XRT alone <break></break> Phase 1: 45 Gy <break></break> Phase 2: 20 Gy</td><td align="left" rowspan="1" colspan="1">5 yrs remission </td></tr><tr><td align="center" colspan="5" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="4" colspan="1">Schlemmer et al. 2008 [<xref rid="B21" ref-type="bibr">18</xref>] </td><td align="left" rowspan="4" colspan="1">Retrospective study</td><td align="left" rowspan="1" colspan="1">32 patients</td><td align="left" rowspan="1" colspan="1">Paclitaxel</td><td align="left" rowspan="1" colspan="1">5/8 PR (mean 5.8 mos)</td></tr><tr><td align="left" rowspan="1" colspan="1">8 scalp and facial</td><td align="left" rowspan="1" colspan="1">± Sx</td><td align="left" rowspan="1" colspan="1">1/8 CR (42 mos)</td></tr><tr><td align="left" rowspan="1" colspan="1">Rest other sites</td><td align="left" rowspan="1" colspan="1">± XRT</td><td align="left" rowspan="1" colspan="1">1/8 PD (3 mos)</td></tr><tr><td align="left" rowspan="1" colspan="1"> </td><td align="left" rowspan="1" colspan="1">± chemotherapy</td><td align="left" rowspan="1" colspan="1">1/8 NC (2 mos) </td></tr><tr><td align="center" colspan="5" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="3" colspan="1">Nagano et al. 2007 [<xref rid="B22" ref-type="bibr">19</xref>] </td><td align="left" rowspan="3" colspan="1">Retrospective study 9 patients </td><td align="left" rowspan="3" colspan="1">Cutaneous AS</td><td align="left" rowspan="3" colspan="1">Docetaxel with or without other previous treatment (XRT, SX) </td><td align="left" rowspan="1" colspan="1">6/9: major response (2 CR, 4 PR)</td></tr><tr><td align="left" rowspan="1" colspan="1">2CR: 2 XRT without SX</td></tr><tr><td align="left" rowspan="1" colspan="1">4 PR: 1 XRT + SX, 1 XRT without SX, 1 SX without XRT, 1 without SX nor XRT </td></tr><tr><td align="center" colspan="5" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="1" colspan="1">Holloway et al. 2005 [<xref rid="B24" ref-type="bibr">20</xref>]</td><td align="left" rowspan="1" colspan="1">Case report</td><td align="left" rowspan="1" colspan="1">Cutaneous AS (scalp)</td><td align="left" rowspan="1" colspan="1">Liposomal doxorubicin + XRT</td><td align="left" rowspan="1" colspan="1">4 years response duration </td></tr><tr><td align="center" colspan="5" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="2" colspan="1">Eiling et al. 2002 [<xref rid="B25" ref-type="bibr">21</xref>] </td><td align="left" rowspan="2" colspan="1">Case report</td><td align="left" rowspan="2" colspan="1">Cutaneous AS (scalp)</td><td align="left" rowspan="2" colspan="1">Liposomal doxorubicin + XRT</td><td align="left" rowspan="1" colspan="1">CR with cervical lymph node metastasis disappearance</td></tr><tr><td align="left" rowspan="1" colspan="1">4 mos response duration </td></tr><tr><td align="center" colspan="5" rowspan="1"><hr></hr></td></tr><tr><td align="left" rowspan="1" colspan="1">Lankester et al. 1999 [<xref rid="B26" ref-type="bibr">22</xref>]</td><td align="left" rowspan="1" colspan="1">Case report</td><td align="left" rowspan="1" colspan="1">Cutaneous AS (face and scalp)</td><td align="left" rowspan="1" colspan="1">Liposomal daunorubicin + XRT</td><td align="left" rowspan="1" colspan="1">15 mos CR</td></tr></tbody></table><table-wrap-foot><fn><p>CR: complete response, PR: partial response, NC: no change, PD: progression of disease, XRT: radiotherapy, SX: surgery.</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002402 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002402 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |